Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Berghmans

Showing results (21-30 of 149) with videos related to

Pageof 15
Sort By:
Revue Des Maladies Respiratoires|May 10, 2015
[Introduction to the Thematic Series "Targeted therapies in lung cancers"]T Berghmans, J Mazières
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 1, 1995
Paclitaxel-induced cutaneous toxicityT Berghmans, J Klastersky
Revue Des Maladies Respiratoires|March 18, 2018
[Evolution and revolution in systemic treatment of lung cancer. The new role of immunotherapy]M Duruisseaux, T Berghmans
Revue Medicale De Bruxelles|October 1, 1992
[Small-cell lung cancer: survival analysis over the last 10 years: 1980-1990]T Berghmans, J Klastersky
Revue Des Maladies Respiratoires|July 27, 2023
[Olimetastatic disease: Current status and perspectives in non-small cell lung cancer]T Berghmans, M Brandão
Revue Des Maladies Respiratoires|January 6, 2021
[Perioperative treatment for resected non-small cell lung cancer: Which option in 2020?]M Coureau, T Berghmans
Revue Medicale De Bruxelles|June 28, 2017
[Immunotherapy and non-small cell lung cancer : a (r)evolution]T Berghmans, A P Meert
Intensive Care Medicine|June 29, 2004
Is there any usefulness for a specific scoring system in assessing the prognosis of cancer patients admitted to the intensive care unit?T Berghmans, J P Sculier
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Is the tolerance to MIP chemotherapy different between English and other European populations?T Berghmans, J P Sculier
Revue Des Maladies Respiratoires|March 2, 2023
[Respiratory cancer diseases: Which role for intensive care ?]T Berghmans, A-P Meert
Pageof 15

Showing results (21-30 of 149) with videos related to

Sort By:
Pageof 15
Revue Des Maladies Respiratoires|May 10, 2015
[Introduction to the Thematic Series "Targeted therapies in lung cancers"]T Berghmans, J Mazières
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 1, 1995
Paclitaxel-induced cutaneous toxicityT Berghmans, J Klastersky
Revue Des Maladies Respiratoires|March 18, 2018
[Evolution and revolution in systemic treatment of lung cancer. The new role of immunotherapy]M Duruisseaux, T Berghmans
Revue Medicale De Bruxelles|October 1, 1992
[Small-cell lung cancer: survival analysis over the last 10 years: 1980-1990]T Berghmans, J Klastersky
Revue Des Maladies Respiratoires|July 27, 2023
[Olimetastatic disease: Current status and perspectives in non-small cell lung cancer]T Berghmans, M Brandão
Revue Des Maladies Respiratoires|January 6, 2021
[Perioperative treatment for resected non-small cell lung cancer: Which option in 2020?]M Coureau, T Berghmans
Revue Medicale De Bruxelles|June 28, 2017
[Immunotherapy and non-small cell lung cancer : a (r)evolution]T Berghmans, A P Meert
Intensive Care Medicine|June 29, 2004
Is there any usefulness for a specific scoring system in assessing the prognosis of cancer patients admitted to the intensive care unit?T Berghmans, J P Sculier
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Is the tolerance to MIP chemotherapy different between English and other European populations?T Berghmans, J P Sculier
Revue Des Maladies Respiratoires|March 2, 2023
[Respiratory cancer diseases: Which role for intensive care ?]T Berghmans, A-P Meert
Pageof 15